Levocetirizine Hcl 5 mg + Montelukast 10 mg
| Composition | Levocetirizine Hcl 5 mg + Montelukast 10 mg |
|---|---|
| Packing | 10x10 Alu/Alu |
| MRP | ₹ 1200 |
| Dosage Form | Tablets |
Ziacet-M Tablet is a dual-action allergy and asthma relief combination containing Levocetirizine HCl 5 mg and Montelukast 10 mg. While Levocetirizine blocks histamine to rapidly relieve sneezing, itching, and runny nose, Montelukast blocks leukotrienes — inflammatory chemicals that trigger nasal congestion, airway narrowing, and prolonged inflammation.
Together, these two complementary mechanisms make Ziacet-M particularly effective for patients with allergic rhinitis accompanied by asthma or exercise-induced bronchoconstriction. The combination addresses symptoms that antihistamines alone do not fully control, offering broader and more sustained relief.
This medicine is commonly used for:
Ziacet-M is indicated for the symptomatic treatment of seasonal and perennial allergic rhinitis, including cases complicated by asthma or elevated airway inflammation. Montelukast is indicated as an adjunct for the prophylaxis and chronic treatment of asthma in adults, and for the relief of symptoms of seasonal allergic rhinitis. The combination provides histaminergic and leukotriene-mediated symptom control simultaneously.
Levocetirizine quickly blocks histamine receptors to stop sneezing, itching, and watery eyes. Montelukast works by blocking leukotrienes — different allergy and inflammation chemicals that cause the airways to swell and the nose to become congested. Together, they tackle two separate pathways of allergic inflammation, providing more complete relief than either drug alone.
Levocetirizine is a selective peripheral H1-receptor antagonist that rapidly attenuates histamine-mediated early-phase allergic responses. Montelukast is a selective, competitive cysteinyl leukotriene receptor-1 (CysLT1) antagonist. It blocks the action of LTC4, LTD4, and LTE4 — potent mediators released from mast cells and eosinophils that drive mucosal oedema, bronchospasm, and eosinophilic airway inflammation in late-phase allergic responses. By combining blockade of both histaminergic and leukotriene pathways, Ziacet-M provides more comprehensive attenuation of the allergic inflammatory cascade.
Leukotrienes are 1,000 times more potent than histamine in causing bronchospasm, which is why blocking them with Montelukast is important in allergy-related asthma — and why adding it to an antihistamine provides meaningfully better control than either drug alone.
Ziacet-M is generally taken once daily in the evening, as directed by your doctor. The evening timing is common because Montelukast is typically taken at night for asthma, and Levocetirizine also suits evening dosing. Take it with or without food. Always follow your doctor's prescribed schedule.
Always follow the dosage and schedule advised by your doctor — this is general guidance only.
The most common side effects are mild and include headache, drowsiness, dry mouth, and stomach upset. Montelukast has been associated with rare mood-related changes — inform your doctor promptly if you notice unusual changes in behaviour, mood, or sleep. Tell your doctor if any side effect is severe or persistent.
An antihistamine is enough to control all allergy symptoms including nasal congestion.
Antihistamines mainly control histamine-driven symptoms like sneezing and itching. Nasal congestion in allergic rhinitis is heavily driven by leukotrienes, which require a drug like Montelukast (in Ziacet-M) to effectively control.
Montelukast in Ziacet-M works like a steroid.
Montelukast is not a steroid. It is a leukotriene receptor antagonist — a non-steroidal anti-inflammatory agent that specifically blocks leukotriene signals without the side effects associated with corticosteroids.